Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (527)	10/25/2001 9:46:30 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 550

Thursday October 25, 9:37 am Eastern Time Genentech cancer drug reaches clinical goal early NEW YORK, Oct 25 (Reuters) - Genentech Inc. (NYSE:DNA - news) said its kidney cancer drug reached a key clinical goal earlier than expected and that the National Cancer Institute therefore stopped recruiting people into a mid-stage clinical trial. South San Francisco, California-based Genentech said data gleaned so far proved that its Avastin drug, which blocks the growth of blood vessels that feed cancerous tumors, works in principal. Now the company needs to show that the drug shows results in a larger trial. Genentech, a biotechnology company that specializes in developing drugs for life-threatening medical conditions, said it has asked an independent board to further analyze its data to help determine the significance of the results. ``We will work closely with the NCI and the U.S. Food and Drug Administration to determine next steps based on this independent review,'' said Gwen Fyfe, Genentech's senior director of Oncology.